Trials / NCT06024057
An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA
Not yet recruiting N/A Gene therapy
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Treatment
- LX101
- Gene
- RPE65
- Conditions
- To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
- Ages
- 18 Years to no upper limit
- Enrollment
- 3 participants
- Started
- 2023-09-01
- Main results expected
- 2028-09-30
- Results posted
- Not yet
- Record last updated
- 2023-09-05
What the study is testing
To evaluate the scaling clinical trail of AAV2-RPE65 gene therapy agent (LX101) in patients with congenital amaurosis (LCA).
Where it runs
No sites listed yet.